Notícias de Wuxi Apptec H

Últimas notícias

Manchetes no idioma original da fonte.

• 
  Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River (abre em uma nova aba)

  GlobeNewswire · 29 de set. de 2026

• 
  Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTec (abre em uma nova aba)

  GlobeNewswire · 24 de set. de 2026

• 
  Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave (abre em uma nova aba)

  GlobeNewswire · 24 de set. de 2026

• Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Drug Development ROI (abre em uma nova aba)

  23 de set. de 2026

• Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market Share (abre em uma nova aba)

  23 de set. de 2026

• Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global Market (abre em uma nova aba)

  23 de set. de 2026

• Capitalize on the Toxicology Testing Services Market Shift: Benchmark Labcorp, Charles River, Eurofins, SGS and WuXi AppTec to Secure Growth and Outpace Disruption (abre em uma nova aba)

  23 de set. de 2026

• Recent Price Trend in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) is Your Friend, Here's Why (abre em uma nova aba)

  22 de set. de 2026

• Capitalize on the ADME-Toxicology Testing Shift: Benchmark Charles River, Thermo Fisher, Eurofins, WuXi AppTec and Evotec to Accelerate R&D ROI and Outpace Disruption (abre em uma nova aba)

  22 de set. de 2026

• 
  Long-Acting Oligonucleotide Development: Dosing, Yield and Stability Questions (abre em uma nova aba)

  GlobeNewswire · 10 de set. de 2026

• 
  Oligonucleotide Drug Delivery Is Moving Beyond the Liver (abre em uma nova aba)

  GlobeNewswire · 3 de set. de 2026

• 
  WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion (abre em uma nova aba)

  PR Newswire · 31 de ago. de 2026

• Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Is a Great Choice for 'Trend' Investors, Here's Why (abre em uma nova aba)

  27 de ago. de 2026

• Here's Why Momentum in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Should Keep going (abre em uma nova aba)

  11 de ago. de 2026

• Judge blocks US decision to add WuXi to list of firms tied to Chinese military (abre em uma nova aba)

  7 de ago. de 2026

• 
  WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model (abre em uma nova aba)

  PR Newswire · 3 de ago. de 2026

• 
  WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year (abre em uma nova aba)

  PR Newswire · 22 de jul. de 2026

• 
  Integrated Development Helps Targeted Protein Degraders Reach the Clinic (abre em uma nova aba)

  GlobeNewswire · 6 de jul. de 2026

• 
  Complex Small Molecules Are Changing Drug R&D (abre em uma nova aba)

  GlobeNewswire · 26 de jun. de 2026

• 
  WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026 (abre em uma nova aba)

  PR Newswire · 27 de abr. de 2026

• Top China Biopharma Stocks to Watch, According to Bernstein (abre em uma nova aba)

  Investing.com · 30 de set. de 2026